Asset Details
Do you wish to reserve the book?
The effect of sodium valproate on chronic daily headache and its subgroups
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The effect of sodium valproate on chronic daily headache and its subgroups
Do you wish to request the book?
The effect of sodium valproate on chronic daily headache and its subgroups
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The effect of sodium valproate on chronic daily headache and its subgroups
2008
Overview
The objective of the study was to assess the efficacy and tolerability of sodium valproate (VPA) on chronic daily headache (CDH) in a prospective, double-blind, randomized, placebo-controlled trial. Seventy patients were included in the study. Twenty-nine had chronic migraine (CM) and 41 had chronic tension-type headache (CTTH). VPA and placebo were applied for 3 months to 40 and 30 patients, respectively. Visual analog scale (VAS) and pain frequency (PF) were used for evaluation. VPA decreased the maximum pain VAS levels (MaxVAS) and PF at the end of the study (
P
= 0.028 and
P
= 0.000, respectively), but did not change general pain VAS (GnVAS) levels (
P
= 0.198). In CM patients, the decreases in MaxVAS, GnVAS and PF parameters were more in VPA treated patients (
P
= 0.006,
P
= 0.03, and
P
= 0.000, respectively). VPA treatment caused more reduction in PF than placebo in the CTTH subgroup (
P
= 0.000). VPA is effective in the prophylactic treatment of CDH by reducing MaxVAS levels and PF. It was more effective in CM than in CTTH.
Publisher
Springer Milan,Springer Nature B.V
Subject
/ Adult
/ Aged
/ Anticonvulsants - administration & dosage
/ Anticonvulsants - adverse effects
/ Chronic Disease - drug therapy
/ Female
/ Headache Disorders - classification
/ Headache Disorders - drug therapy
/ Headache Disorders - prevention & control
/ Humans
/ Male
/ Medicine
/ Original
/ Pain Measurement - drug effects
/ Pain Threshold - drug effects
/ Placebos
/ Tension-Type Headache - drug therapy
/ Tension-Type Headache - prevention & control
